Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1135 | 2019 |
A survey of liver transplantation from living adult donors in the United States RS Brown Jr, MW Russo, M Lai, ML Shiffman, MC Richardson, ... New England Journal of Medicine 348 (9), 818-825, 2003 | 601 | 2003 |
The clinical significance of persistently normal ALT in chronic hepatitis B infection M Lai, BJ Hyatt, I Nasser, M Curry, NH Afdhal Journal of hepatology 47 (6), 760-767, 2007 | 465 | 2007 |
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 373 | 2020 |
GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease R Loomba, Z Kayali, M Noureddin, P Ruane, EJ Lawitz, M Bennett, ... Gastroenterology 155 (5), 1463-1473. e6, 2018 | 320 | 2018 |
The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase PJ White, RW McGarrah, PA Grimsrud, SC Tso, WH Yang, JM Haldeman, ... Cell metabolism 27 (6), 1281-1293. e7, 2018 | 280 | 2018 |
Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension N Chalasani, MF Abdelmalek, G Garcia-Tsao, R Vuppalanchi, N Alkhouri, ... Gastroenterology 158 (5), 1334-1345. e5, 2020 | 277 | 2020 |
Saroglitazar, a PPAR‐α/γ agonist, for treatment of NAFLD: a randomized controlled double‐blind phase 2 trial S Gawrieh, M Noureddin, N Loo, R Mohseni, V Awasty, K Cusi, ... Hepatology 74 (4), 1809-1824, 2021 | 269 | 2021 |
Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis P An, LL Wei, S Zhao, DY Sverdlov, KA Vaid, M Miyamoto, K Kuramitsu, ... Nature communications 11 (1), 2362, 2020 | 239 | 2020 |
ChREBP regulates fructose-induced glucose production independently of insulin signaling MS Kim, SA Krawczyk, L Doridot, AJ Fowler, JX Wang, SA Trauger, ... The Journal of clinical investigation 126 (11), 4372-4386, 2019 | 217 | 2019 |
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis M Kornek, M Lynch, SH Mehta, M Lai, M Exley, NH Afdhal, D Schuppan Gastroenterology 143 (2), 448-458, 2012 | 216 | 2012 |
Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis EB Tapper, D Finkelstein, MA Mittleman, G Piatkowski, M Lai Hepatology 62 (2), 584-590, 2015 | 207 | 2015 |
Fibrosis assessment in nonalcoholic fatty liver disease (NAFLD) in 2016 DH Kaswala, M Lai, NH Afdhal Digestive diseases and sciences 61, 1356-1364, 2016 | 193 | 2016 |
The performance of vibration controlled transient elastography in a US cohort of patients with nonalcoholic fatty liver disease EB Tapper, T Challies, I Nasser, NH Afdhal, M Lai Official journal of the American College of Gastroenterology| ACG 111 (5 …, 2016 | 177 | 2016 |
A quality improvement initiative reduces 30-day rate of readmission for patients with cirrhosis EB Tapper, D Finkelstein, MA Mittleman, G Piatkowski, M Chang, M Lai Clinical Gastroenterology and Hepatology 14 (5), 753-759, 2016 | 163 | 2016 |
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension G Garcia-Tsao, J Bosch, Z Kayali, SA Harrison, MF Abdelmalek, E Lawitz, ... Journal of hepatology 72 (5), 885-895, 2020 | 148 | 2020 |
Liver fibrosis determination. M Lai, NH Afdhal Gastroenterology Clinics of North America 48 (2), 281-289, 2019 | 114 | 2019 |
Cost-effective evaluation of nonalcoholic fatty liver disease with NAFLD fibrosis score and vibration controlled transient elastography EB Tapper, N Sengupta, MMG Hunink, NH Afdhal, M Lai Official journal of the American College of Gastroenterology| ACG 110 (9 …, 2015 | 89 | 2015 |
Cost-effectiveness analysis: risk stratification of nonalcoholic fatty liver disease (NAFLD) by the primary care physician using the NAFLD fibrosis score EB Tapper, MGM Hunink, NH Afdhal, M Lai, N Sengupta PLoS One 11 (2), e0147237, 2016 | 72 | 2016 |
Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: a prospective cohort study EB Tapper, M Lai Hepatology 63 (4), 1184-1189, 2016 | 71 | 2016 |